NRx Q3 net operating loss down 74% to $1.6M; on track for NDA filings by year-end

NRX Pharmaceuticals, Inc.

Net operating loss $1.6M in Q3 2024 vs $6.1M in Q3 2023; nine-month net loss $16.1M vs $25.8M.
Cash $1.6M at Sep 30; closed $5.4M second tranche from Anson Funds post-quarter; $10.8M total convertible debt.
Expects to file NDAs for NRX-100 (IV ketamine) and NRX-101 (bipolar depression) by end of 2024, with 2025 PDUFA dates.
HOPE Therapeutics signed two non-binding LOIs to acquire Interventional Psychiatry Clinics; first revenue forecast by year-end 2024.
Retired Streeterville debt at substantial discount; litigation settled.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.